Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA says Zicam enforcement routine

This article was originally published in The Tan Sheet

Executive Summary

FDA says simultaneously announcing a consumer safety alert and sending a warning letter to Matrixx Initiatives about the risks of Zicam zinc-containing intranasal homeopathic products due to potential loss of smell is not an unusual action, as some industry stakeholders suggest. Center for Drug Evaluation and Research officials say "warning letters are issued to achieve voluntary compliance," such as the agency's June 16 communication with Matrixx about Zicam. "When it is consistent with the public protection responsibilities of the agency and depending on the nature of the violation, it is FDA's practice to give firms an opportunity to take voluntary and prompt corrective actions before it initiates an enforcement action," CDER said July 13. Matrixx voluntarily recalled the products the same day it received the warning letter (1"The Tan Sheet" June 29, 2009)

You may also be interested in...

FDA Uses "Unusual" Action To Get Matrixx's Zicam Off The Market

In a rare action, FDA simultaneously alerted consumers not to use Matrixx Initiatives' intranasal Zicam products because of potential safety problems and warned Matrixx to remove the products from market without first consulting with the firm

Evusheld: UK Urged To Use RWD To Give Clinically Vulnerable Early Access To COVID-19 Treatment

A full appraisal by the UK cost watchdog is not the only way to gauge the safety and effectiveness of Evusheld, argues the independent Drug Safety Research Unit in response to the government’s decision not to buy the licensed COVID-19 drug because of insufficient data on protection. 

Torrent’s $245m Curatio Deal Gives Pole Position In Fast-Growing Cosmetic Dermatology

Torrent’s $245m acquisition of Curatio Healthcare has moved it up a rank to No.7 in the overall Indian pharmaceutical market apart from making it the market leader in cosmetic dermatology. While it’s a pricey deal, factors like growing prevalence of skin diseases and shift towards e-commerce bode well for future revenue growth in a nascent market

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts